Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
225 Leser
Artikel bewerten:
(1)

Higher-Education Institutions Turn to Mentavi Health to Reduce Diagnostic Delays and Support Student Success

Mentavi's clinically validated, asynchronous ADHD assessment - recently published in the Journal of Clinical Psychiatry - shortens wait times from months to days and empowers students to access timely support.

GRAND RAPIDS, MICHIGAN / ACCESS Newswire / September 25, 2025 / As the back-to-school season begins, the strain of transition extends beyond students to parents, professors, and staff. Limited campus resources often mean long waits for ADHD, anxiety, or depression evaluations, delaying care and harming academic performance.

Mentavi Health's clinically validated, asynchronous Diagnostic Evaluation - the first online assessment for adult ADHD validated against the current standard of care and now peer-reviewed and published in the Journal of Clinical Psychiatry - reduces waits from weeks to days, giving students timely answers when they matter most.

"Early identification and treatment of ADHD and related mental health conditions is crucial for improved clinical outcomes," said Mentavi Health Chief Medical Officer Barry K. Herman, M.D., MMM. "Timely diagnosis allows students to access the right accommodations and support to stay on track academically and personally."

Mentavi now serves more than a dozen higher-education institutions nationwide and has completed over 20,000 student evaluations, demonstrating both the scalability of its services and the value institutions place on timely, validated mental health support. Publication in the Journal of Clinical Psychiatry, one of the field's leading peer-reviewed journals, further underscores Mentavi's commitment to scientific rigor and expanding evidence-based access to care.

"For many of our students, the greatest challenge isn't the classroom itself but the invisible barriers that prevent them from accessing the accommodations they are entitled to under federal law," said Jana Garnett, DSPS Coordinator/Director at Santa Barbara City College. "By making professional diagnoses accessible and affordable, Mentavi gives our students a pathway to the support they need to persist and succeed in college."

Efficient and affordable support

Students can complete the Diagnostic Evaluation independently in one to two hours. Each evaluation is reviewed by a licensed, doctorate-level clinician - not automated AI - with results delivered within five days. Students may then share their results with the appropriate offices at their college or university to discuss accommodations or treatment options when warranted.?

Alternatively, in over 40 states, students can choose to meet with a Mentavi clinician to explore therapy, medical treatment, or coaching. This flexibility allows institutions to either keep students within their own health systems or to expand support through Mentavi's nationwide network. At $189 per evaluation, Mentavi's service is also far more affordable than traditional in-clinic assessments.

Improved student outcomes and institutional reputation

Early and accurate diagnosis empowers students to understand their challenges, access the right support, and adopt strategies that improve performance, strengthen retention, and build adaptability for life after graduation. For institutions, providing timely answers demonstrates a commitment to student well-being and reduces the risk of students falling behind.

"With national discussions underway about stimulant and non-stimulant treatments, and with increasing state-level scrutiny of AI in healthcare, Mentavi stands out by combining validated assessments with a human-centered model: every evaluation is reviewed by a licensed clinician, ensuring accuracy and accountability," said Keith Brophy, CEO of Mentavi Health.

"Our mission has always been to make clinically validated mental health care accessible and affordable. As the new school year begins, higher-education institutions seek proven ways to support their students while managing limited resources. By partnering with Mentavi, colleges and universities can offer timely, evidence-based diagnosis and care as appropriate that reduces the stress families, faculty, and staff feel during this critical transition period."

For more information, visit Mentavi Health or ADHD Online. The Mentavi Health Diagnostic Evaluation is clinically validated for the diagnosis of ADHD in adults. Study results were published in the Journal of Clinical Psychiatry on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; doi:10.4088/JCP.25m15846).

About Mentavi Health and ADHD Online

Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Mental Health Diagnostic Evaluation and various treatment options showcase the company's commitment to providing comprehensive, accessible, compliant online mental health care. For more information, visit mentavi.com.

Media contact:

Tim Cox, ZingPR for Mentavi Health
tim@zingpr.com

.

SOURCE: Mentavi Health

Related Images



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/higher-education-institutions-turn-to-mentavi-health-to-reduce-diagno-1077812

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.